Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Intuitive Surgical stock falls 2.32 percent before Q3 report

Analyst upgrade Earnings report AI-generated analysis

📉 Intuitive Surgical stock closed down 2.32% at $391.95 on October 2, 2026, despite strong underlying quarterly performance.

💰 Q2 revenue surged to $2.89 billion, representing an 18.4% year-over-year increase from $2.44 billion in the prior year.

📈 Net profit climbed to $818.1 million, up from $658.4 million in the same quarter of 2025.

🌍 International procedure growth reached 20% in Q2 2026, providing a strong counterbalance to domestic trends.

📉 Domestic da Vinci procedure growth decelerated to 12% in Q2 2026 from 14% in Q1 2025.

🎯 RBC Capital analyst Kendall Au maintains a Buy rating with a $575 price target, $183 above the current stock price.

📅 The company is scheduled to report its next quarterly results on October 20, 2026.

🏛️ Intuitive Surgical holds a market capitalization of $138.5 billion as of October 2, 2026.

📊 Shares trade within a 52-week range of $328.57 to $603.88 on the Nasdaq exchange.

🔮 Management maintains full-year guidance for procedure growth between 13.5% and 15.5%.

Bullish Signals
  • Intuitive Surgical reported Q2 revenue of $2.89 billion, an 18.4% increase year-over-year, demonstrating strong top-line growth.
  • Net profit for the quarter rose to $818.1 million from $658.4 million in the prior year period.
  • International procedure growth accelerated to 20% in Q2 2026, indicating successful global expansion.
  • RBC Capital maintains a Buy rating with a $575 price target, suggesting significant upside potential from current levels.
  • Management reaffirmed full-year guidance for da Vinci procedure growth between 13.5% and 15.5%.
Risk Factors
  • Domestic da Vinci procedure growth slowed to 12% in Q2 2026, down from 14% in the previous quarter.
  • Stock price fell 2.32% to close at $391.95 on October 2, 2026, reflecting near-term market hesitation despite earnings beat.
  • Investors are questioning whether current procedure growth rates can be sustained into the second half of 2026.
Full Analysis
Intuitive Surgical (ISRG) shares fell 2.32% to close at $391.95 on October 2, 2026, despite reporting strong Q2 results that significantly outperformed the prior year. The company posted revenue of $2.89 billion, an 18.4% increase from $2.44 billion in the same quarter of 2025, while net profit rose to $818.1 million from $658.4 million. Analyst sentiment remains bullish with RBC Capital maintaining a Buy rating and setting a $575 price target, which stands $183 above the current closing price. However, market attention is focused on whether the company can sustain its growth trajectory into the second half of 2026, particularly given recent deceleration in domestic procedure growth. Domestic da Vinci procedure growth slowed to 12% in Q2 2026 compared to 14% in the previous quarter, though international expansion continues to drive momentum with a robust 20% growth rate. Management has maintained its full-year guidance for procedure growth between 13.5% and 15.5%, keeping valuation and execution capabilities central to investor debate ahead of the October 20 earnings report.